Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

CTI BioPharma Corp. (CTIC)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
2.7200-0.0400 (-1.45%)
At close: 4:00PM EDT
2.7900 +0.07 (+2.57%)
After hours: 06:06PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Momentum

Momentum

Previous Close2.7600
Open2.8300
Bid2.7000 x 1000
Ask2.7100 x 1000
Day's Range2.6800 - 2.8400
52 Week Range2.1500 - 4.1300
Volume752,475
Avg. Volume767,056
Market Cap253.803M
Beta (5Y Monthly)0.76
PE Ratio (TTM)N/A
EPS (TTM)-0.7970
Earnings DateNov 08, 2021 - Nov 12, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est7.28
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for CTIC

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • CTI BioPharma Corp.
    Analyst Report: Bristol-Myers Squibb CompanyBristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, oncology, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
    Rating
    Fair Value
    Economic Moat
    8 days agoMorningstar
View more
Advertisement
Advertisement